TrialSignal
Clinical trial intelligence report
Examination of Efficacy and Safety of SERM or Bisphosphonates After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03755193
Status
RECRUITING
Phase
PHASE2
Sponsor
Shinshu University
Executive brief
Investment-Ready Snapshot
This clinical trial, sponsored by Shinshu University, aims to evaluate the efficacy and safety of different anti-resorption drugs (SERM and bisphosphonates) following a 2-year denosumab therapy in Japanese osteoporosis patients. The study is currently recruiting participants and is expected to complete by November 2026.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03755193
Indication
Osteoporosis
Modality
monoclonal antibody
Target
SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug", Bisphosphonates and ELD "Edirol®Tablet 0.75ug", ELD "Edirol®Tablet 0.75ug"
Intervention
SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug", Bisphosphonates and ELD "Edirol®Tablet 0.75ug", ELD "Edirol®Tablet 0.75ug"
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.